What’s Ahead for Agenus Inc (NASDAQ:AGEN) After More Shorted Shares?

June 17, 2018 - By Adrian Mccoy

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It is positive, as 11 investors sold Agenus Inc. shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported.
Point72 Asset Mngmt Limited Partnership reported 3.47 million shares. Blair William And Il has 48,810 shares for 0% of their portfolio. Morgan Stanley holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 350,424 shares. Goldman Sachs holds 0% in Agenus Inc. (NASDAQ:AGEN) or 307,353 shares. State Board Of Administration Of Florida Retirement System, a Florida-based fund reported 21,464 shares. Jump Trading Limited Liability Company holds 13,902 shares or 0.01% of its portfolio. Balyasny Asset Ltd Liability reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Weiss Multi has 0.01% invested in Agenus Inc. (NASDAQ:AGEN). Stratos Wealth Prns Limited, a Ohio-based fund reported 194 shares. Sg Americas Securities Ltd Liability Com accumulated 0% or 15,751 shares. Barclays Public Lc has 0% invested in Agenus Inc. (NASDAQ:AGEN). The New York-based Metropolitan Life Ny has invested 0% in Agenus Inc. (NASDAQ:AGEN). State Street invested in 0% or 3.18 million shares. Crestwood Advisors Group Ltd Limited Liability Company accumulated 32,928 shares. Ameritas Investment Prtnrs invested in 5,577 shares or 0% of the stock.

The stock of Agenus Inc (NASDAQ:AGEN) registered an increase of 1.46% in short interest. AGEN’s total short interest was 10.35 million shares in June as published by FINRA. Its up 1.46% from 10.20M shares, reported previously. With 1.56 million shares average volume, it will take short sellers 7 days to cover their AGEN’s short positions. The short interest to Agenus Inc’s float is 13.15%.

The stock decreased 3.57% or $0.1 during the last trading session, reaching $2.7. About 2.18M shares traded or 49.59% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since June 17, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $280.80 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: